Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Strathcona Resources (OTCPK:STHRF) said Friday it formally launched its offer to acquire MEG Energy (OTCPK:MEGEF) that values ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

The acquisition grants Eli Lilly and Company (NYSE:LLY) access to SiteOne’s pipeline, including its lead compound currently in Phase 2 trials. Analyst Evan Seigerman of BMO described the ...

Eli Lilly (NYSE:LLY) recently announced promising ... to a spectacular 400% return in the past five years. LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock. LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to ...